Seasoned healthcare-focused investor and operator with experience executing growth equity and venture investments across biotech, medical devices, and services. Ryan M Palmer brings operational leadership in scaling commercial strategies, board governance, and capital formation for early-to-late-stage companies. Known for sourcing cross-border partnerships, structuring growth rounds and driving exit readiness through commercialization milestones and strategic M&A. Relevant to funds targeting healthcare innovation, commercialization risk reduction and value creation pre-exit.
Seasoned healthcare-focused investor and operator with experience executing growth equity and venture investments across biotech, medical devices, and services. Ryan M Palmer brings operational leadership in scaling commercial strategies, board governance, and capital formation for early-to-late-stage companies. Known for sourcing cross-border partnerships, structuring growth rounds and driving exit readiness through commercialization milestones and strategic M&A. Relevant to funds targeting healthcare innovation, commercialization risk reduction and value creation pre-exit.
Preference for healthcare growth equity and venture investments that prioritize commercialization pathways and measurable clinical or market milestones. Capital is allocated to companies where operational intervention—commercial scaling, KOL engagement, regulatory‑de-risking and cross‑border partnerships—can materially accelerate value. Investment style favors staged financings, lead or active board roles, syndication to optimize capital and exit optionality, and sector focus on biotech, medical devices and services with a 3–7 year exit horizon driven by M&A or strategic partnerships.
Preference for healthcare growth equity and venture investments that prioritize commercialization pathways and measurable clinical or market milestones. Capital is allocated to companies where operational intervention—commercial scaling, KOL engagement, regulatory‑de-risking and cross‑border partnerships—can materially accelerate value. Investment style favors staged financings, lead or active board roles, syndication to optimize capital and exit optionality, and sector focus on biotech, medical devices and services with a 3–7 year exit horizon driven by M&A or strategic partnerships.
| Trades 977 | Longs Won 729/977 74% | Profit Factor 10.7 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $483,090.16 |
| Average Win $121,088.68 | Best Trade (Jul 16) $9.88M | Sharpe Ratio -64.99 |
| Average Loss -$33,260.18 | Worst Trade (Dec 30) -$419,607.49 | Z-Score 10.6 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 5d | Expectancy $81,909.03 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 7,692 | 6,923 | 6,154 | 5,385 | 4,615 | 3,846 | 3,077 | 2,308 | 1,538 | 769 |